Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ABCC9 | O60706 | 4/20 | 0.34 |
| ▸ | KCNA5 | P22460 | 7/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2009715 | 1.00 | CYP3A4 (0.36) | CYP3A4KDM4ECYP2C19HIF1AMEN1 | |
| SCHEMBL2878901 | 0.93 | ABCC9 (0.39) | CYP3A4KDM4ECYP2C19HIF1AMEN1 | |
| SCHEMBL2008357 | 0.93 | ABCC9 (0.39) | CYP3A4KDM4ECYP2C19HIF1AMEN1 | |
| SCHEMBL2887474 | 0.91 | KDM4E (0.36) | CYP3A4KDM4ECYP2C19HIF1AABCC9 | |
| SCHEMBL2007181 | 0.91 | KDM4E (0.36) | CYP3A4KDM4ECYP2C19HIF1AABCC9 | |
| SCHEMBL3596079 | 0.91 | ABCB1 (0.43) | CYP3A4KDM4ECYP2C19HIF1AKMT2A | |
| SCHEMBL2008329 | 0.91 | ABCB1 (0.43) | CYP3A4KDM4ECYP2C19HIF1AKMT2A | |
| SCHEMBL2008331 | 0.91 | ABCB1 (0.43) | CYP3A4KDM4ECYP2C19HIF1AKMT2A | |
| SCHEMBL2881077 | 0.91 | ABCB1 (0.43) | CYP3A4KDM4ECYP2C19HIF1AKMT2A | |
| SCHEMBL2878169 | 0.90 | ABCC9 (0.35) | CYP3A4KDM4ECYP2C19HIF1AABCC9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069374-A1 | Tricyclic benzopyrane compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069374-A1 | Tricyclic benzopyrane compound | CBR1, CBR3, CYP2C9 | CYP3A4 131/4885KDM4E 3259/4885CYP2C19 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.